Fluorinated conformationally restricted γ-aminobutyric acid aminotransferase inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 25, 2006, Pages 7404-7412

  Lu, Hejun ^a   Silverman, Richard B ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 4 (2,2,2 TRIFLUORO 1 TRIFLUOROMETHYLETHYLIDENE)CYCLOPENTANECARBOXYLIC ACID; 3 AMINO 4 (2,2,2 TRIFLUOROETHYLIDENE)CYCLOPENTANECARBOXYLIC ACID; 4 AMINO 3 FLUOROCYCLOPENT 2 ENECARBOXYLIC ACID; 4 AMINO 3 PENTAFLUOROETHYLCYCLOPENT 2 ENECARBOXYLIC ACID; 4 AMINO 3 TRIFLUOROMETHYLCYCLOPENT 2 ENECARBOXYLIC ACID; 4 AMINOBUTYRATE AMINOTRANSFERASE; AMINOTRANSFERASE INHIBITOR; ANTICONVULSIVE AGENT;

ANIMAL TISSUE; ARTICLE; CONFORMATIONAL TRANSITION; DRUG CONFORMATION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; FLUORINATION; NONHUMAN;

4-AMINOBUTYRATE TRANSAMINASE; ANIMALS; ANTICONVULSANTS; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CYCLOPENTANES; FLUORINE; HEPTANES; KINETICS; MOLECULAR CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; VIGABATRIN;

EID: 33845473826     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0608715     Document Type: Article

References (59)

1. McGeer, E. G.; McGeer, P. L.; Thompson, S. GABA and Glutamate Enzymes. In Glutamine, Glutamate, and GABA in the Central Nervous System: Hertz, L., Kvamme, E., McGeer, E. G., Schousboe, A., Eds.; Liss: New York, 1983; pp 3-17.
2. Baxter, C. F.; Roberts, E. The γ-Aminobutyric Acid-α- Ketoglutaric Acid Transaminase of Beef Brain. J. Biol. Chem. 1958, 233, 1135-1139.
3. Karlsson, A.; Fonnum, F.; Malthe-Sorrensen, D.; Storm-Mathisen, J. Effect of the convulsive agent 3-mercaptopropionic acid on the levels of GABA, other amino acids and glutamate decarboxylase in different regions of the rat brain. Biochem. Pharmacol. 1974, 23, 3053-3061.
4. Gale, K. GABA in epilepsy; the pharmacologie basis. Epilepsia 1989, 30 (Suppl. 3), S1-S11.
5. Bakay, R. A. E.; Harris, A. B. Neurotransmitter receptor and biochemical changes in mondey cortical epileptic foci. Brain Res. 1981, 206, 387-404.
6. Loyd, K. G.; Munari, C.; Bossi, L.; Stoeffels, C.; Talairach, J.; Morselli, P. L. Biochemical Evidence for the Alterations of GABA-Mediated Synaptic Transmission in Pathological Brain Tissue (Stereo EEG or Morphological Definition) from Epileptic Patients. In Neurotransmission, Seizures, Epilepsy; Morselli, P. L., Loescher, W., Loyd, K. G., Eds.; Raven Press: New York, 1981; pp 325-338.
7. (a) Perry, T. L.; Hansen, S.; Lesk, D.; Kloster, M. Amino Acids in Plasma, Cerebrospinal Fluid, and Brain of Patients with Huntington's Chorea. Adv. Neurol. 1972, 1, 609-618.
8. (b) McGeer, P. L.; McGeer, E. G. The GABA System and Function of the Basal Ganglia: Huntington's Disease. In GABA in Nervous System Function: Roberts, E., Chase, T. N., Tower, D. B., Eds.: Raven Press: New York. 1976; pp 487-495.
9. (a) Butterworth, J.; Yates, C. M.; Simpson, J. Phosphate-activated glutaminase in relation to Huntington's disease and agonal state. J. Neurochem. 1983, 41, 440-447.
10. (b) Spokes, E. G. S. Brain temperature after death. J. Neurosci. Methods 1980, 2, 105-106.
11. (c) Wu, J. Y.; Bird, E. D.; Chen, M. S.; Huang, W. M. Abnormalities of neurotransmitter enzymes in Huntington's chorea. Neurochem. Res. 1979, 4, 575-586.
12. (d) Iversen, L. L.; Bird, E. D.; Mackay, A. V. P.; Rayner, C. N. Analysis of glutamate decarboxylase in post-mortem brain tissue in Huntington's chorea. J. Psychiatr. Res. 1974, 11, 255-256.
13. Nishino, N.; Fujiwara, H.; Noguchi-Kuno, S.-A.; Tanaka, C. GABA receptor but not muscarinic receptor density was decreased in the brain of patients with Parkinson's disease. Jpn. J. Pharmacol. 1988, 48, 331-339.
14. (a) Maker, H. S.; Weiss, C.; Weissbarth, S.; Silides, D. J.; Whetsell, W. Regional activities of metabolic enzymes and glutamate decarboxylase in human brain. Ann. Neurol. 1981, 10, 377-383.
15. (b) Rinne, U. K.; Laaksonen, H.; Riekkinen, P.; Sonninen, V. Brain glutamic acid decarboxylase activity in Parkinson's disease. Eur. Neurol. 1974, 12, 13-19.
16. (c) McGeer, P. L.; McGeer, E. G.; Wada, J. A.; Jung, E. Effects of globus pallidus lesions and Parkinson's disease on brain glutamic acid decarboxylase. Brain Res. 1971, 32, 425-431.
17. (a) Aoyagi, T.; Wada, T.; Nagai, M.; Kojima, F.; Harada, S.; Takeuchi, T.; Takahashi, H.; Hirokawa, K.; Tsumita, T. Increased γ-aminobutyrate aminotransferase activity in brain of patients with Alzheimer's disease. Chem. Pharm. Bull. 1990, 38, 1748-1749.
18. (b) Davies, P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res. 1979, 171, 319-327.
19. (c) Perry, E. K.; Gibson, P. H.; Blessed, G.; Perry, R. H.; Tomlinson, B. E. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necripsy brain tissue. J. Neurol. Sci. 1977, 34, 247-265.
20. (d) Bowen, D. M.; White, P.; Flack, R. H. A.; Smith, C. B.; Davison, N. A. Brain-decarboxylase activities as indices of pathological change in senile dementia. Lancet 1974, 1, 1247-1249.
21. (e) Kodama, K.; Kaitani, H.; Nanba, M.; Kondo, T.; Mikame, F.; Yoshida, H.; Sato, K.; Yanaihara, N. Neurotransmitter analogs in body fluids of patients with dementia. Shinkei Kagaku 1981, 20, 496.
22. Gunne, L. M.; Haeggstroem, J. E.; Sjoequist, B. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis. Nature (London) 1984, 309, 347-349.
23. (a) Johnston, G. A. R.; Curtis, D. R.; Beart, P. M.; Game, C. J. A.; McColloch, R. M.; Twichin, B. Cis- and trans-4-aminocrotonic acid as GABA analogues of restricted conformation. J. Neurochem. 1975, 24, 157-160.
24. 3H]GABA uptake into the satellite glial cells of rat sensory ganglia. Brain Res. 1974, 66, 289-300.
25. (c) Johnston, G. A. R.; Stephanson, A. L.; Twichin, B. Piperazic acid and related compounds as inhibitors of GABA uptake in rat brain slices. J. Pharm. Pharmacol. 1977, 29, 240-241.
26. (d) Brehm, L.; Hjeds, H.; Krogsgarrd-Larsen, P. The structure of muscimol, a GABA analogue of restricted conformation. Acta Chem. Scand. 1972, 26, 1298-1299.
27. (e) Krogsgaard-Larsen, P.; Johnston, G. A. R.; Lodge, D.; Curtis, D. R. A new class of GABA agonist. Nature (London) 1977, 268, 53-55.
28. (f) Beart, P. M.; Curtis, D. R.; Johnston, G. A. R. 4-Aminotetrolic acid: new conformational-restricted analogue of γ-aminobutyric acid. Nature (London), New Biol. 1971, 234, 80-81.
29. (g) Beart, P. M.; Johnston, G. A. R. GABA [γ-aminobutyric acid] uptake in rat brain slices. Inhibition by GABA analogs and by various drugs. Aust. J. Chem. 1972, 25, 1359-1361.
30. (a) Silverman, R. B. Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology; CRC Press: Boca Raton, FL, 1988; Vols. I and II.
31. (b) Silverman, R. B. Mechanism-Based Enzyme Inactivators. Methods Enzymol. 1995, 249, 240-283.
32. Nanavati, S. M.; Silverman, R. B. Design of potential anticonvulsant agents: mechanistic classification of GABA aminotransferase inactivators. J. Med. Chem. 1989, 32, 2413-2421.
33. Lippert, B.; Metcalf, B. W.; Jung, M. J.; Casara, P. 4-Amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur. J. Biochem. 1977, 74, 441-445.
34. Loscher, W. Comparative assay of anticonvulsant and toxic potencies of sixteen GABAmimetic drugs. Neuropharmacology 1982, 21, 803-810.
35. (a) Tassinari, C. A.; Michelucci, R.; Ambrosetto, G.; Salvi, F. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch. Neurol. 1987, 44, 907-910.
36. (b) Browne, T. R.; Mattson, R. J.; Penry, J. K.; Smith, D. B.; Treiman, D. M.; Wilder, B. J.; Ben-Menachem, E.; Miketta, R. M.; Sherry, K. M.; Szabo, G. K. A multicentre study of vigabatrin for drug-resistant epilepsy. Br. J. Clin. Pharmacol. 1989, 27, 95S-100S.
37. (c) Sivenius, M. R.; Ylinen, A.; Murros, K.; Matilainen, R.; Riekkinen, P. Double-blind dose reduction study of vigabatrin in complex partial epilepsy. Epilepsia 1987, 28, 688-692.
38. Dewey, S. L.; Morgan, A. E.; Ashby, C. R., Jr.; Horan, B.; Kushner, S. A.; Logan, J.; Volkow, N. D.; Fowler, J. S.; Gardner, E. L.; Brodie, J. D. A novel strategy for the treatment of cocaine addiction. Synapse 1998, 30, 119-129.
39. Dewey, S. L.; Brodie, J. D.; Gerasimov, M.; Horan, B.; Gardner, E. L.; Ashby, C. R., Jr. A pharmacologic strategy for the treatment of nicotine addiction. Synapse 1999, 31, 76-86.
40. Gerasimov, M. R.; Ashby, C. R.; Gardner, E. L.; Mills, M. J.; Brodie, J. D.; Dewey, S. L. Gamma-vinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 1999, 34, 11-19.
41. Kushner, S. A.; Dewey, S. L.; Kornetsky, C. The irreversible γ-aminobutyric acid (GABA) transaminase inhibitor γ-vinyl-GABA blocks cocaine self-administration in rats. J. Pharmacol. Exp. Ther. 1999, 290, 797-802.
42. (a) Nanavati, S. M.; Silverman, R. B. Mechanism of inactivation of γ-aminobutyric acid aminotransferase by the antiepilepy drug γ-vinyl GABA (vigabatrin). J. Am. Chem. Soc. 1991, 113, 9341-9349.
43. (b) Allan, R. D.; Twitchin, B. Synthesis of analogues of GABA. IV Three unsaturated derivatives of 2-aminocyclopentane-1-carboxylic acid. Aust. J. Chem. 1980, 33, 599-604.
44. (c) Allan, R. D., Fong, J. Synthesis of analogues of GABA. XV. Preparation and resolution of some potent cyclopentene and cyclopentane derivatives. Aust. J. Chem. 1986, 39, 855-864.
45. (d) Galeazzi, R.; Mobbili, G.; Orena, M. Modeling and synthesis of conformationally restricted amino acids. Curr. Org. Chem. 2004, 8, 1799-1929.
46. Qiu, J.; Pingsterhaus, J.; Silverman, R. B. Inhibition and substrate activity of conformationally rigid vigabatrin analogues with γ-aminobutyric acid aminotransferase. J. Med. Chem. 1999, 42, 4725-4728.
47. Pan, Y.; Qiu, J.; Silverman, R. B. Design, synthesis, and biological activity of a difluoro-substituted, conformationally rigid vigabatrin analogue as a potent γ-aminobutyric acid aminotransferase inhibitor. J. Med. Chem. 2003, 46, 5292-5293.
48. (a) Park, B. K.; Kitteringham, N. R.; O'Neill, P. M. Metabolism of fluorine-containing drugs. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 443-470.
49. (b) Ismail, F. M. D. Important fluorinated drugs in experimental and clinical use. J. Fluorine Chem. 2002, 118, 27-33.
50. Iseki, K. Asymmetric Fluoroalkylation. In Enantiocontrolled Synthesis of Fluoro-organic Compounds; Soloshonok, V. A., Ed.; John Wiley & Sons: New York, 2001; pp 33-62.
51. For a recent review, see the following: Pongdee, R.; Liu, H.-W. Elucidation of enzyme mechanisms using fluorinated substrate analogues. Bioorg. Chem. 2004, 32, 393-437.
52. Qiu, J.; Silverman, R. B. A new class of conformationally rigid analogues of 4-amino-5-halopentanoic acids, potent inactivators of γ-aminobutyric acid aminotransferase. J. Med. Chem. 2000, 43, 706-720.
53. Krishnamurti, R.; Bellew, D. R.; Prakash, G. K. S. Preparation of trifluoromethyl and other perfluoroalkyl compounds with (perfluoroalkyl) trimethylsilanes. J. Org. Chem. 1991, 56, 984-989.
54. Chen, Q.; Wu, S. Methyl (fluorosulfonyl)difluoroacetate; a new trifluoromethylating agent. J. Chem. Soc., Chem. Commun. 1989, 705-706.
55. Natuzzi, D.; Daddabbo, L.; Stipani, V.; Cappello, A. R.; Miniero, D. V.; Capobianco, L.; Stipani, I. Inactivation of the reconstituted oxoglutarate carrier from bovine heart mitochondria by pyridoxal 5′-phosphate. J. Bioenerg. Biomembr. 1999, 31, 535-541.
56. Yamazaki, T.; Hiraoka, S.; Kitazume, T. Ready carbon-carbon bond formation of 2-(trifluoromethyl)acrylate via Michael addition reactions. J. Org. Chem. 1994, 59, 5100-5103.
57. Koo, Y. K.; Nandi, D.; Silverman, R. B. Multiple active enzyme species of γ-aminobutyric acid aminotransferase are not isozymes, but are proteolytic fragments. Arch. Biochem. Biophys. 2000, 374, 248-254.
58. Jeffery, D.; Weitzman, P. D. J.; Lunt, G. G. An improved assay for 4-aminobutyrate:2-oxoglutarate aminotransferase. Insect Biochem. 1988, 28, 347-349.
59. Scott, E. M.; Jakoby, W. B. Soluble γ-aminobutyric-glutamic transaminase from Pseudomonas fluorescens. J. Biol. Chem. 1958, 234, 932-936.